Psychological distress related to BRCA testing in ovarian cancer patients

被引:24
作者
Bjornslett, Merete [1 ,2 ]
Dahl, Alv A. [2 ,3 ]
Sorebo, Oystein [4 ]
Dorum, Anne [5 ]
机构
[1] Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Mol Oncol, N-0424 Oslo, Norway
[2] Univ Oslo, Fac Med, Oslo, Norway
[3] Oslo Univ Hosp, Norwegian Radium Hosp, Natl Advisory Ctr Late Effects Canc Treatment, Dept Oncol, Oslo, Norway
[4] Buskerud & Vestfold Univ Coll, Sch Business & Social Sci, Honefoss, Norway
[5] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Gynecol Oncol, Oslo, Norway
关键词
Ovarian cancer; Oncology; BRCA; MICRA; Anxiety; HEREDITARY BREAST; DEPRESSION SCALE; HOSPITAL ANXIETY; RISK; QUESTIONNAIRE; MUTATIONS; DESIGN; IMPACT; WOMEN;
D O I
10.1007/s10689-015-9811-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
An increasing demand for genetic testing has moved the procedure from highly selected at-risk individuals, now also including cancer patients for treatment associated testing. The heritable fraction of ovarian cancer is more than 10 %, and our department has offered BRCA testing to such patients irrespective of family history since 2002. This study examined potential psychosocial distress associated with this procedure using The Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire and other patient-rated generic distress instruments. Patients were divided into four groups according to cancer risk: mutation carriers, own history of breast cancer and ovarian cancer, family history of breast cancer and/or ovarian cancer, and patients without family history. In a postal survey, 354 patients responded. Good acceptance of the MICRA was observed, and previously described good psychometric properties were confirmed. A significant association between MICRA total score and receiving a positive BRCA test result was found. No significant between-group differences were observed with generic distress instruments. Time since cancer diagnosis, test result, and survey showed no significant associations with MICRA scores. Internal consistencies of instruments were adequate. Exploratory and confirmatory factor analyses showed adequate fit indices for a three factor solution of the MICRA, but further refinement of the items should be considered. In conclusion, the specific types of worry and distress most relevant to receiving genetic testing irrespective of family history were not captured by the generic distress instruments. The MICRA was supported as a useful tool for detection of mental distress related to genetic testing and risk evaluation.
引用
收藏
页码:495 / 504
页数:10
相关论文
共 50 条
  • [41] Psychological Distress, Anxiety, and Depression of Cancer-Affected BRCA1/2 Mutation Carriers: a Systematic Review
    Ringwald, Johanna
    Wochnowski, Christina
    Bosse, Kristin
    Giel, Katrin Elisabeth
    Schaffeler, Norbert
    Zipfel, Stephan
    Teufel, Martin
    JOURNAL OF GENETIC COUNSELING, 2016, 25 (05) : 880 - 891
  • [42] Experiences and interpretations of BRCA1/2 testing among women affected by breast or ovarian cancer who received a negative result
    Stafford, Lesley
    Flehr, Alison
    Judd, Fiona
    Lindeman, Geoffrey J.
    Gibson, Penny
    Komiti, Angela
    Mann, G. Bruce
    Kentwell, Maira
    JOURNAL OF COMMUNITY GENETICS, 2019, 10 (04) : 501 - 514
  • [43] Family History and BRCA1/BRCA2 Status Among Japanese Ovarian Cancer Patients and Occult Cancer in a BRCA1 Mutant Case
    Hirasawa, Akira
    Masuda, Kenta
    Akahane, Tomoko
    Ueki, Arisa
    Yokota, Megumi
    Tsuruta, Tomohiko
    Nomura, Hiroyuki
    Kataoka, Fumio
    Tominaga, Eiichiro
    Banno, Kouji
    Makita, Kazuya
    Susumu, Nobuyuki
    Sugano, Kokichi
    Kosaki, Kenjiro
    Kameyama, Kaori
    Aoki, Daisuke
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 44 (01) : 49 - 56
  • [44] Physical and psychological distress amongst patients undergoing neoadjuvant chemotherapy for advanced ovarian cancer
    Mokshagundam, Shilpa
    McGree, Michaela E.
    Tapia, Amanda L.
    Fought, Angela J.
    Ishitani, Karen P.
    Lee, Minji K.
    Dowdy, Sean C.
    Yadav, Siddhartha
    Pachman, Deirdre R.
    Kumar, Amanika
    GYNECOLOGIC ONCOLOGY, 2024, 190 : 230 - 235
  • [45] Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients
    Singer, Christian F.
    Tan, Yen Y.
    Muhr, Daniela
    Rappaport, Christine
    Gschwantler-Kaulich, Daphne
    Grimm, Christoph
    Polterauer, Stephan
    Pfeiler, Georg
    Berger, Andreas
    Tea, Muy-Kheng M.
    CANCER MEDICINE, 2019, 8 (04): : 1875 - 1881
  • [46] Longitudinal outcomes with cancer multigene panel testing in previously tested BRCA1/2 negative patients
    Bradbury, Angela R.
    Egleston, Brian L.
    Patrick-Miller, Linda J.
    Rustgi, Neil
    Brandt, Amanda
    Brower, Jamie
    DiGiovanni, Laura
    Fetzer, Dominique
    Berkelbach, Christopher
    Long, Jessica M.
    Powers, Jacquelyn
    Stopfer, Jill E.
    Domchek, Susan M.
    CLINICAL GENETICS, 2020, 97 (04) : 601 - 609
  • [47] Prophylactic mastectomy for BRCA mutation carriers after ovarian cancer treatment: is it beneficial?
    Kotsopoulos, Joanne
    Narod, Steven A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (03) : 199 - 200
  • [48] Psychosocial impact of BRCA testing in young Black breast cancer survivors
    Gonzalez, Brian D.
    Hoogland, Aasha, I
    Kasting, Monica L.
    Cragun, Deborah
    Kim, Jongphil
    Ashing, Kimlin
    Holt, Cheryl L.
    Halbert, Chanita Hughes
    Pal, Tuya
    Vadaparampil, Susan T.
    PSYCHO-ONCOLOGY, 2018, 27 (12) : 2778 - 2785
  • [49] Use of Germline BRCA Testing in Patients With Ovarian Cancer and Commercial Insurance
    Cham, Stephanie
    Landrum, Mary Beth
    Keating, Nancy L.
    Armstrong, Joanne
    Wright, Alexi A.
    JAMA NETWORK OPEN, 2022, 5 (01) : E2142703
  • [50] Bevacizumab As Maintenance Treatment in Patients With Ovarian Cancer: Wait for BRCA Testing
    Farolfi, Alberto
    Lorusso, Domenica
    Pignata, Sandro
    De Giorgi, Ugo
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (02) : 172 - +